Jaeschke, Georg,Lindemann, Lothar,Ricci, Antonio,Rueher, Daniel,Stadler, Heinz,Vieira, Eric
申请号：
NZ70514413
公开号：
NZ705144A
申请日:
2013.10.15
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH R1 is fluoro or chloro R2 is hydrogen or methyl wherein the compound of general formula I is (3,3-dimethyl-morpholin-4-yl)-[5-(3-chloro-phenylethynyl)-pyrimidin-2-yl]-methanone, (3,3-dimethyl-morpholin-4-yl)-[5-(3-fluoro-phenylethynyl)-pyridin-2-yl]-methanone, [5-(3-chloro-phenylethynyl)-pyridin-2-yl]-morpholin-4-yl-methanone, or (3,3-dimethyl-morpholin-4-yl)-[5-(3-chloro-phenylethynyl)-pyridin-2-yl]-methanone or a pharmaceutically acceptable acid addition salt thereof. The compounds of general formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson’s disease, and gastroesophageal reflux disease (GERD).
